

# ORE PHARMACEUTICAL HOLDINGS INC. (ORXE)

## 15-12G

Notice of termination of registration of a class of securities under Section 12(g)

Filed on 9/24/2010

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 15

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number: 0-23317

ORE PHARMACEUTICAL HOLDINGS INC.  
(Exact name of registrant as specified in its charter)  
One Main Street, Suite 300  
Cambridge, Massachusetts 02142  
(Address of Principal Executive Offices)

(617) 649-2001  
(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

Common Stock, \$0.01 Par Value  
(Title of each class of securities covered by this Form)

None  
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1)	<input checked="" type="checkbox"/>
Rule 12g-4(a)(2)	<input type="checkbox"/>
Rule 12h-3(b)(1)(i)	<input checked="" type="checkbox"/>
Rule 12h-3(b)(1)(ii)	<input type="checkbox"/>
Rule 15d-6	<input type="checkbox"/>

Approximate number of holders of record as of the certification or notice date: 124

Pursuant to the requirements of the Securities Exchange Act of 1934, Ore  
Pharmaceutical Holdings Inc. has caused this certification and notice to be  
signed on its behalf by the undersigned duly authorized person.

Date: September 24, 2010

By: /s/ Mark J. Gabrielson

-----  
Mark J. Gabrielson  
President and Chief Executive Officer